Phase Ib trial of an extended-release formulation of aripiprazole in schizophrenia

Trial Profile

Phase Ib trial of an extended-release formulation of aripiprazole in schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2012

At a glance

  • Drugs Aripiprazole lauroxil (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Dec 2012 Data will be presented at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP - Poster 174), according to an Alkermes media release.
    • 31 Oct 2012 Status changed from not stated to completed.
    • 17 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top